bobbybobby
MarketsStocksJoin Us

Precigen, Inc

PGEN

$7.74

-9.37%

Bobby Quantitative Model
Oct 5, 2026

PGEN

Precigen, Inc

$7.74

-9.37%
Oct 5, 2026
Bobby Quantitative Model

Related headlines

Bearish
uniQure Plunges 37% on Mixed Huntington's Data
Bullish
AbbVie's Juvmo FDA Approval: A Parkinson's Game-Changer
Bullish
Vertex Kidney Drug Shines in Phase II: Time to Buy VRTX?
Bullish
Insmed's Arikayce FDA Filing Accepted: What It Means for INSM Stock
Neutral
XENE Epilepsy NDA Filed, Depression Setback: What Investors Need to Know

People also watch

Vertex Pharmaceuticals

Vertex Pharmaceuticals

VRTX

Analysis
Moderna

Moderna

MRNA

Analysis
Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

REGN

Analysis
Revolution Medicines, Inc. Common Stock

Revolution Medicines, Inc. Common Stock

RVMD

Analysis
Alnylam Pharmaceuticals

Alnylam Pharmaceuticals

ALNY

Analysis

PGEN price trend

Historical Price
Current Price $7.74
Average Target $7.74
High Target $8.90
Low Target $6.58

Wall Street consensus

Most Wall Street analysts maintain a constructive view on Precigen, Inc's 12-month outlook, with a consensus price target around $13.65 and implied upside of +76.4% versus the current price.

Average Target

$13.65

0 analysts

Implied Upside

+76.4%

vs. current price

Analyst Count

—

covering this stock

Price Range

$11 - $18

Analyst target range

Drowning in data?

Find the real signal!

Drowning in data?

Find the real signal!

PGEN Technical Analysis

Beta

0.92

0.92x market volatility

Max Drawdown

-40.5%

Largest decline past year

52-Week Range

$3-$9

Price range past year

Annual Return

+138.2%

Cumulative gain past year

PeriodPGEN ReturnS&P 500
1m+9.0%+0.6%
3m+40.5%+3.6%
6m+87.9%+14.6%
1y+138.2%+15.8%
ytd+80.8%+13.6%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

PGEN Fundamental Analysis

Quarterly Revenue

$54978000.0B

2026-06

Revenue YoY Growth

N/A

YoY Comparison

Gross Margin

94.9%

Latest Quarter

Free Cash Flow

$-115826000.0B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Product
Service

Open an Account, get $2 TSLA now!

Open an Account, get $2 TSLA now!

Valuation Analysis: Is PGEN Overvalued?

PE

-3.0x

Latest Quarter

vs. Historical

N/A

5-Year PE Range 17x~59x

vs. Industry Avg

N/A

Industry PE ~N/A*

EV/EBITDA

-5.5x

Enterprise Value Multiple

Related headlines

Bearish
uniQure Plunges 37% on Mixed Huntington's Data
Bullish
AbbVie's Juvmo FDA Approval: A Parkinson's Game-Changer
Bullish
Vertex Kidney Drug Shines in Phase II: Time to Buy VRTX?
Bullish
Insmed's Arikayce FDA Filing Accepted: What It Means for INSM Stock
Neutral
XENE Epilepsy NDA Filed, Depression Setback: What Investors Need to Know

People also watch

Vertex Pharmaceuticals

Vertex Pharmaceuticals

VRTX

Analysis
Moderna

Moderna

MRNA

Analysis
Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

REGN

Analysis
Revolution Medicines, Inc. Common Stock

Revolution Medicines, Inc. Common Stock

RVMD

Analysis
Alnylam Pharmaceuticals

Alnylam Pharmaceuticals

ALNY

Analysis

Product

Partner

Markets

Stocks

© 2026 FLOW AI PTE. LTD. All Rights Reserved.

Bobby, the world's first financial AI Agent, is developed by Flow AI, an AI-driven company. Flow AI is dedicated to providing global investors with AI-powered financial services across multiple markets.

Waffo.com Limited (authorised distributor): RM 1903, 19/F Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong.

Bobby
cs@bobby.ai
Bobby AI
RockFlow Platform
Stock Event
Macro Event
Industry Event
NVDA
AAPL
MSFT
AMZN
GOOG
META
TSLA
Privacy Policy
Terms of Use